Navigation Links
Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
Date:12/2/2013

LAVAL, Quebec, Dec. 2, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem the remaining $465.5 million aggregate principal amount of its outstanding 6.50% Senior Notes due 2016 CUSIP Nos. 91911XAR5, U9098VAH5 (the "Notes") and has mailed an irrevocable notice of redemption for the Notes. On November 15, 2013, Valeant Pharmaceuticals International mailed an irrevocable notice of redemption for $450 million aggregate principal amount of the Notes.

On December 2, 2013, a copy of the irrevocable notice of redemption with respect to the remaining Notes was mailed to record holders of the Notes by The Bank of New York Mellon Trust Company, N.A., 400 South Hope Street, Suite 400, Los Angeles, CA 90071, as trustee under the indenture governing the Notes.

This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Caution Regarding Forward-Looking Information and "Safe Harbor" Statement
This press release may contain forward-looking statements, including, but not limited to, the redemption of our notes. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in our most recent annual and quarterly reports and detailed from time to time in our other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. We undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, except as required by law.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
2. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
3. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
4. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
5. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
6. Valeant Pharmaceuticals Announces Continuance
7. Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results
8. Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb
9. Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013
10. Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares
11. Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 23, 2017  HealthMine surveys with 9,250 insured consumers ... health plan members want help from their plans in ... in their health, 2) help closing gaps in care, ... health and 5) relevant, real-time guidance. Meeting these needs ... costs. A Reason to Stay ...
(Date:3/24/2017)... , Mar 24, 2017 The Board ... the company,s Annual Report 2016 including the complete 2016 Annual ... and available on Nordic Nanovector,s website in the section Investor ... ... IR enquiries: Tone Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis By Procedure, Replacement Procedure By Technique, Repair Procedure By Technique, ... ... Devices Market is forecasted to grow at a CAGR of 13.35% ... is driven by rising aging population, growth in population with heart ...
Breaking Medicine Technology:
(Date:3/25/2017)... Square, PA (PRWEB) , ... March 25, 2017 , ... ... priority as a public relations partner. , All through the year, Garden Media ... and press releases, working with key influencers and pitching client’s key messages ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... from third world countries to hospitals in the United States, it’s a threat ... on the current obstacles facing infection prevention and offers strategies for the healthcare ...
(Date:3/24/2017)... , ... March 24, 2017 , ... The iaedp Foundation, ... other medical professionals caring for those suffering from the full spectrum of disordered eating, ... as eating disorders professionals from nearly all 50 states and several countries converged on ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... are now offering treatments for sleep apnea and TMJ at their office. TMJ, ... apnea , specifically the obstructive type, is increasingly being treated at dental offices ...
(Date:3/24/2017)... Southlake, Texas (PRWEB) , ... March 24, 2017 ... ... make 2017 the year of enhancements, upgrading their training and leads programs. , ... Empower University. Reserved for elite sales agents, Performance Partners is designed to teach ...
Breaking Medicine News(10 mins):